CB2

CB2 Related Products (50):

By Type:	Pan (25) Selective (17)
By Effects:	Inhibitors (2) Agonists (37) Antagonists (9) Modulator (1)

Cat. No.	Product Name	Effect	Purity

HY-10863

Anandamide	Agonist	≥99.0%
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis.

HY-13439

SR144528	Antagonist	99.25%
SR144528 is a potent and selective CB2 receptor antagonist with a K_i of 0.6 nM.

HY-W005629

Leelamine	Agonist	98.36%
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells.

HY-100197

Synaptamide	Agonist	99.30%
Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenous metabolite and structural analogue of Anandamide. Synaptamide binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties. Synaptamide is the first small-molecule endogenous ligand of an adhesion G protein-coupled receptor (aGPCR) .

HY-13505

AM281	Antagonist	≥99.0%
AM281 is a selective CB1 receptor antagonist with an IC₅₀ of 9.91 nM. AM281 inhibits CB2 receptor with an IC₅₀ of 13000 nM.

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Agonist
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively.

HY-110036

GW-405833	Agonist	99.12%
GW-405833 (L768242) is a potent, selective cannabinoid receptor 2 (CB₂) agonist with an EC₅₀ of 50.7 nM. GW-405833 also behaves as a noncompetitive CB₁ antagonist. GW-405833 suppresses inflammatory and neuropathic pain.

HY-128872

Etrinabdione	Agonist	99.16%
Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB₂ receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity.

HY-131004

CB2R PAM	Agonist	98.46%
CB2R PAM is an orally active cannabinoid type-2 receptors (CB2Rs) positive allosteric modulator. CB2R PAM displays antinociceptive activity in vivo in an experimental mouse model of neuropathic pain.

HY-121852

SCH 336	Agonist	98.85%
SCH 336 is a potent, selective, inverse and orally active CB2 agonist. SCH 336 inhibits BaF3/CB2 migration. SCH 336 significantly inhibits the migration of leukocytes in vivo. SCH 336 blocks ovalbumin-induced lung eosinophilia in mice.

HY-100488

Bay 59-3074	Agonist	98.60%
Bay 59-3074 is a selective cannabinoid CB₁/CB₂ receptor partial agonist with K_i values of 48.3 and 45.5 nM at human CB₁ and CB₂ receptors, respectively. Bay 59-3074 has analgesic properties.

HY-116637

Tetrahydromagnolol	Agonist	99.79%
Tetrahydromagnolol (Magnolignan), a main metabolite of Magnolol, is a potent and selective cannabinoid CB2 receptor agonist with an EC₅₀ of 170 nM and a K_i of 416 nM. Tetrahydromagnolol possesses 20-fold more selective for CB2 receptor than CB1 receptor. Tetrahydromagnolol is also a weak GPR55 receptor antagonist.

HY-119104

AZD1940	Agonist	99.58%
AZD1940 is an orally active, high affinity cannabinoid CB1/CB2 receptor agonist with pK_i values of 7.93 and 9.06 for human CB1R and CB2R, respectively. AZD1940 shows a robust analgesia action.

HY-14788

Drinabant	Antagonist	≥99.0%
Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC₅₀ values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.

HY-14900

Tedalinab	Agonist	99.94%
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment.

HY-152581

CB2R antagonist 3	Antagonist	98.08%
CB2R antagonist 3 is a selective antagonist of cannabinoid type 2 receptor (CB2R). CB2R antagonist 3 has high affinity for human CB2R and specific selectivity for CB1R. CB2R antagonist 3 can be combined with CB65 (HY-110047), the activator of CB2R. CB2R antagonist 3 effectively up-regulates the expression of anti-inflammatory cytokines and down-regulates the expression of pro-inflammatory cytokines.

HY-150029

CB1/2 agonist 3	Agonist	99.83%
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a CB1/CB2 (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively.

HY-147512

CB1/2 agonist 1	Agonist	99.20%
CB1/2 agonist 1 is a potent and cross the blood-brain barrier CB1/2 agonist with EC₅₀s of 56.15, 11.63 nM for CB1R and CB2R, respectively. CB1/2 agonist 1 reduces glutamate release and LPS-induced activation of microglial cells. CB1/2 agonist 1 shows anti-inflammatory and antinociceptive effects. CB1/2 agonist 1 has the potential for the research of multiple sclerosis.

HY-135419

CB2 modulator 1	Modulator	99.75%
CB2 modulator 1 (compound 130) is a potent CB2 modulator. CB2 modulator 1 has the potential for immunedisorders, inflammation, osteoporosis, renal ischemia.

HY-146134

PGN36	Antagonist	99.74%
PGN36 (Compound 18) is a selective cannabinoid CB₂ receptor (CB₂R) antagonist with a K_i of 0.09 µM.

Name
Email *

	Sorry, but the email address you supplied was invalid.